All In Biotech

Drug Trial Radar · NCT07231861

Bioequivalence Study of AJU-R713 and R713R in Healthy Adult Volunteers

An Open-Label, Randomized, Fasting, Single-Dose, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of "AJU-R713" and "R713R" in Healthy Adult Volunteers

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

62

Actual

Start

Dec 12, 2025

Primary completion

Dec 21, 2025

Study completion Jan 7, 2026

Sponsor

Lead sponsor
AJU Pharm Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To Evaluate the Safety and Pharmacokinetics of Pranlukast hydrate in Healthy Adults.

Conditions

  • Bronchial Asthma
  • Perennial Allergic Rhinitis

Interventions

  • AJU-R713Drug

    Oral formulation

  • R713RDrug

    Oral formulation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax of PranlukastTime frame: 0 hour ~ 24 hour after drug administration
  2. AUCt of PranlukastTime frame: 0 hour ~ 24 hour after drug administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • H Plus Yangji Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.